Market Cap 35.89B
Revenue (ttm) 5.15B
Net Income (ttm) 1.40B
EPS (ttm) N/A
PE Ratio 24.84
Forward PE 22.74
Profit Margin 27.22%
Debt to Equity Ratio 0.07
Volume 2,957,000
Avg Vol 1,136,026
Day's Range N/A - N/A
Shares Out 145.94M
Stochastic %K 18%
Beta 0.87
Analysts Sell
Price Target $289.38

Company Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry,...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 858-836-5000
Address:
9001 Spectrum Center Boulevard, San Diego, United States
SimpleWinningSetups
SimpleWinningSetups Dec. 19 at 7:47 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RMD $240.00 Put · JAN 16, 2026 Exp Entry Price: $5.75 - $6.04 Exit Price Target: $11.27 Profit Margin: +96% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:41 PM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $242.55, showing a bearish sentiment with an RSI of 35.65, indicating potential oversold conditions. The price is below both the 30-day MA (249.81) and the 50-day MA (255.44), suggesting further downside risk. However, the current price is near the 60-day low of 237.63, providing a potential support level. Directional Bias: The bearish trend is evident, but the oversold RSI suggests a possible reversal. If the price can break above the MA30, we may see a short-term bullish move. Trade Plan: - Suggested Entry: $242.55 - Stop Loss: $236.00 (below 60D low) - Take Profit Targets: 1. $250.00 (3% gain) 2. $260.00 (7% gain) 3. $284.00 (17% gain) This plan provides a favorable risk-reward ratio, aiming for a significant return on the third target. Monitor price action closely for confirmation. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 1:04 PM
Stifel updates rating for ResMed ( $RMD ) to Hold, target set at 270 → 260.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:29 AM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $248.26, showing a neutral RSI of 47.42, indicating no immediate overbought or oversold conditions. The price is below both the 30-day MA of 250.07 and the 50-day MA of 256.98, suggesting a bearish short-term trend. However, the stock is within a range defined by a 60-day high of 284.87 and a low of 237.63, providing potential for upward movement. Directional Bias: Given the current price position and RSI, there is potential for a rebound towards the upper range. A break above the 30-day MA could signal a bullish reversal. Trade Plan: - Suggested Entry: $250.00 (above MA30) - Stop Loss: $240.00 (below recent low) - Take Profit Targets: 1. $260.00 (6% gain) 2. $270.00 (8.7% gain) 3. $290.00 (17% gain) This plan offers a clear risk-reward ratio with a potential 17% ROI on the third target. https://privateprofiteers.com
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 16 at 7:41 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RMD $240.00 Put · JAN 16, 2026 Exp Entry Price: $4.84 - $4.90 Exit Price Target: $9.68 Profit Margin: +100% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
St0ckJuggler
St0ckJuggler Dec. 16 at 1:24 PM
$RMD medtech sleep-apnea leader, holding a wide base where a volume breakout can confirm the next leg
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 11:21 AM
Baird has updated their rating for ResMed ( $RMD ) to Neutral with a price target of 275.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 16 at 9:57 AM
$RMD Current Stock Price: $253.16 Contracts to trade: $250 RMD Dec 19 2025 Call Entry: $3.91 Exit: $5.51 ROI: 41% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:02 AM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $252.27, near the middle of its 60-day range ($237.63 - $284.87). The RSI at 51.96 indicates a neutral momentum, suggesting potential for upward movement. The proximity of the last close to the 30-day moving average (MA30) of $249.99 supports a bullish outlook. Directional Bias: The price is above the MA30 but below the MA50 ($257.57), indicating a potential bullish reversal if it breaks above the MA50. The ATR of $5.99 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $253.00 (slightly above last close) - Stop Loss: $245.00 (below MA30) - Take Profit Targets: 1. $262.00 (3.5% gain) 2. $270.00 (6.9% gain) 3. $295.00 (16.9% gain) This plan offers a potential ROI of over 17% on the third target, aligning with market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:55 PM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $252.04, showing strength with an RSI of 59.01, indicating bullish momentum but not overbought. The stock is above its 30-day moving average (MA30) of $249.98, suggesting a positive short-term trend, while the 50-day moving average (MA50) at $258.05 indicates potential resistance. Directional Bias: Given the current price is closer to the 60-day high of $284.87 than the low of $237.63, there is a bullish bias. The ATR of 6.6 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $252.50 - Stop Loss: $245.00 (approx. 3% risk) - Take Profit Targets: 1. $260.00 (3% gain) 2. $270.00 (7% gain) 3. $295.00 (17% gain) With these targets, a solid risk-reward ratio is established, aiming for over 17% ROI on the third target. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Latest News on RMD
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

Nov 24, 2025, 2:15 PM EST - 25 days ago

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDXX


ResMed: Safe Bet For A Recession Environment

Nov 17, 2025, 5:24 PM EST - 4 weeks ago

ResMed: Safe Bet For A Recession Environment


ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript

Oct 30, 2025, 10:16 PM EDT - 7 weeks ago

ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript


ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript

Jul 31, 2025, 9:39 PM EDT - 5 months ago

ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript


Spot Outliers Like ResMed Early with Money Flows

Jul 30, 2025, 6:08 AM EDT - 5 months ago

Spot Outliers Like ResMed Early with Money Flows


Top 15 High-Growth Dividend Stocks For July 2025

Jul 1, 2025, 9:02 PM EDT - 6 months ago

Top 15 High-Growth Dividend Stocks For July 2025

APH BAC BK DKS DPZ ELV GPN


ResMed: A Sleeping Giant Hiding In Plain Sight

Jun 9, 2025, 5:38 AM EDT - 6 months ago

ResMed: A Sleeping Giant Hiding In Plain Sight


Top 15 High-Growth Dividend Stocks For June 2025

Jun 2, 2025, 10:00 AM EDT - 7 months ago

Top 15 High-Growth Dividend Stocks For June 2025

DKS DPZ GPN INTU KLAC LRCX MPWR


Resmed Acquires VirtuOx

May 1, 2025, 9:00 AM EDT - 8 months ago

Resmed Acquires VirtuOx


ResMed: Cornering The Market In Sleep Solutions

Apr 24, 2025, 5:12 AM EDT - 8 months ago

ResMed: Cornering The Market In Sleep Solutions


ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript

Apr 23, 2025, 7:16 PM EDT - 8 months ago

ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript


Resmed Names Salli Schwartz as Chief Investor Relations Officer

Apr 21, 2025, 5:00 PM EDT - 8 months ago

Resmed Names Salli Schwartz as Chief Investor Relations Officer


Jan De Witte joins GHO Capital as Operating Partner

Feb 11, 2025, 4:30 AM EST - 11 months ago

Jan De Witte joins GHO Capital as Operating Partner

IART


Stock Of The Day: Trading The Range In ResMed

Feb 3, 2025, 12:59 PM EST - 11 months ago

Stock Of The Day: Trading The Range In ResMed


ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript

Jan 30, 2025, 9:10 PM EST - 11 months ago

ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript


SimpleWinningSetups
SimpleWinningSetups Dec. 19 at 7:47 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RMD $240.00 Put · JAN 16, 2026 Exp Entry Price: $5.75 - $6.04 Exit Price Target: $11.27 Profit Margin: +96% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:41 PM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $242.55, showing a bearish sentiment with an RSI of 35.65, indicating potential oversold conditions. The price is below both the 30-day MA (249.81) and the 50-day MA (255.44), suggesting further downside risk. However, the current price is near the 60-day low of 237.63, providing a potential support level. Directional Bias: The bearish trend is evident, but the oversold RSI suggests a possible reversal. If the price can break above the MA30, we may see a short-term bullish move. Trade Plan: - Suggested Entry: $242.55 - Stop Loss: $236.00 (below 60D low) - Take Profit Targets: 1. $250.00 (3% gain) 2. $260.00 (7% gain) 3. $284.00 (17% gain) This plan provides a favorable risk-reward ratio, aiming for a significant return on the third target. Monitor price action closely for confirmation. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 1:04 PM
Stifel updates rating for ResMed ( $RMD ) to Hold, target set at 270 → 260.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:29 AM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $248.26, showing a neutral RSI of 47.42, indicating no immediate overbought or oversold conditions. The price is below both the 30-day MA of 250.07 and the 50-day MA of 256.98, suggesting a bearish short-term trend. However, the stock is within a range defined by a 60-day high of 284.87 and a low of 237.63, providing potential for upward movement. Directional Bias: Given the current price position and RSI, there is potential for a rebound towards the upper range. A break above the 30-day MA could signal a bullish reversal. Trade Plan: - Suggested Entry: $250.00 (above MA30) - Stop Loss: $240.00 (below recent low) - Take Profit Targets: 1. $260.00 (6% gain) 2. $270.00 (8.7% gain) 3. $290.00 (17% gain) This plan offers a clear risk-reward ratio with a potential 17% ROI on the third target. https://privateprofiteers.com
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 16 at 7:41 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RMD $240.00 Put · JAN 16, 2026 Exp Entry Price: $4.84 - $4.90 Exit Price Target: $9.68 Profit Margin: +100% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
St0ckJuggler
St0ckJuggler Dec. 16 at 1:24 PM
$RMD medtech sleep-apnea leader, holding a wide base where a volume breakout can confirm the next leg
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 11:21 AM
Baird has updated their rating for ResMed ( $RMD ) to Neutral with a price target of 275.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 16 at 9:57 AM
$RMD Current Stock Price: $253.16 Contracts to trade: $250 RMD Dec 19 2025 Call Entry: $3.91 Exit: $5.51 ROI: 41% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:02 AM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $252.27, near the middle of its 60-day range ($237.63 - $284.87). The RSI at 51.96 indicates a neutral momentum, suggesting potential for upward movement. The proximity of the last close to the 30-day moving average (MA30) of $249.99 supports a bullish outlook. Directional Bias: The price is above the MA30 but below the MA50 ($257.57), indicating a potential bullish reversal if it breaks above the MA50. The ATR of $5.99 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $253.00 (slightly above last close) - Stop Loss: $245.00 (below MA30) - Take Profit Targets: 1. $262.00 (3.5% gain) 2. $270.00 (6.9% gain) 3. $295.00 (16.9% gain) This plan offers a potential ROI of over 17% on the third target, aligning with market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:55 PM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $252.04, showing strength with an RSI of 59.01, indicating bullish momentum but not overbought. The stock is above its 30-day moving average (MA30) of $249.98, suggesting a positive short-term trend, while the 50-day moving average (MA50) at $258.05 indicates potential resistance. Directional Bias: Given the current price is closer to the 60-day high of $284.87 than the low of $237.63, there is a bullish bias. The ATR of 6.6 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $252.50 - Stop Loss: $245.00 (approx. 3% risk) - Take Profit Targets: 1. $260.00 (3% gain) 2. $270.00 (7% gain) 3. $295.00 (17% gain) With these targets, a solid risk-reward ratio is established, aiming for over 17% ROI on the third target. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
skepticalbee
skepticalbee Dec. 10 at 7:35 PM
$IXHL $RMD Really? Given the intrisically intellectual nature of your post, I'm very eager to hear your logic for this prediction. Care to share?
1 · Reply
skepticalbee
skepticalbee Dec. 10 at 7:27 PM
$IXHL ResMed ($RMD) has annual revenue of over $5 billion, and a current market cap of $36 billion. Does anyone think they might want to take steps to protect this financial empire by making some sort of deal with IXHL, a major disrupter in the multi-billion dollar OSA market? Just putting this back out there for the newbies and others who might have lost sight of this math.
0 · Reply
IldijanaMM
IldijanaMM Dec. 10 at 1:25 PM
$IXHL Look at $RMD going in the pre market! 👀
1 · Reply
IldijanaMM
IldijanaMM Dec. 10 at 10:10 AM
$RMD Can we see a M&A with IXHL that got the worlds best drug for sleep apnea, that just got a Fast track from FDA? I mean 83% reduction in phase 2/3 and zero side effects 🤔 And we moving to Dubai just beside your office!
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:59 AM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $246.52, positioned within a 60-day high of $284.87 and a low of $237.63. The RSI at 50.36 indicates a neutral momentum, suggesting potential for upward movement if buying pressure increases. Directional Bias: The stock is trading below both the 30-day MA of 250.2 and the 50-day MA of 258.87, indicating a bearish short-term trend. However, the proximity to the 60-day low suggests a potential reversal opportunity. Suggested Entry: Enter at $247.00. Stop Loss: Set at $237.00 to limit risk. Take Profit Targets: 1. Target 1: $255.00 (3.25% gain) 2. Target 2: $265.00 (7.27% gain) 3. Target 3: $288.00 (16.83% gain) This plan offers a potential ROI of over 17% on the third target. Monitor the stock closely for momentum shifts. https://privateprofiteers.com
0 · Reply
Chapman211
Chapman211 Dec. 10 at 2:49 AM
$IXHL $RMD up 12 dollars since close. Crazy. Hopefully we follow and see a nice bounce up in the pm tomorrow morning.
1 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 9 at 9:19 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RMD $240.00 Put · DEC 19, 2025 Exp Entry Price: $1.60 - $2.15 Exit Price Target: $3.09 Profit Margin: +93% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 9 at 11:29 AM
$RMD about to heat up? This FDA clearance could be the catalyst traders have been waiting for. The headline points straight to RMD getting a boost from its AI-enabled Smart Comfort winning FDA clearance — and that kind of validation can shift sentiment fast. See what’s driving the setup here 👉 https://www.zacks.com/stock/news/2801393/rmd-stock-set-to-gain-from-fda-clearance-of-ai-enabled-smart-comfort?cid=sm-stocktwits-2-2801393-teaser-23904&ADID=SYND_STOCKTWITS_TWEET_2_2801393_TEASER_23904
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:46 PM
Actionable Trade Alert for $RMD: Market Context: $RMD is currently trading at $252.28, showing a bullish sentiment with an RSI of 60.06, indicating upward momentum but nearing overbought levels. The price is above the 30-day moving average (MA30) of $250.7, suggesting a positive short-term trend. However, it is below the 50-day moving average (MA50) of $259.41, indicating potential resistance ahead. Directional Bias: Given the RSI and the proximity to the MA30, we anticipate a continuation of the upward trend, aiming for the recent high of $284.87. Trade Plan: - Suggested Entry: $252.50 - Stop Loss: $245.00 (approximately 3% below entry) - Take Profit Targets: 1. $265.00 (5% gain) 2. $275.00 (9% gain) 3. $295.00 (17% gain) This plan allows for a favorable risk-reward ratio while capitalizing on the bullish trend. Monitor price action closely, especially around the MA50. https://privateprofiteers.com
0 · Reply
ELTee227
ELTee227 Dec. 8 at 4:14 PM
$RMD Bouncy Bouncy. Up and down she does.
0 · Reply
Ond_Stock_Mind
Ond_Stock_Mind Dec. 7 at 7:03 PM
0 · Reply
It_S_Me
It_S_Me Dec. 7 at 6:18 PM
$RMD $IXHL Phase 2 is the most critical filter in the entire drug development process. Historically, most drugs fail in Phase 2, not in Phase 3. Why? Phase 2 tests whether the drug actually works at all. Phase 3 tests whether it works the same way in a larger patient population. When a drug performs extremely well in Phase 2 (like IHL-42X), the probability of Phase 3 success increases significantly. Biotech statistics show: Typical Phase 2 → Phase 3 success rate: 35–40% But when Phase 2 results are clearly better than expected, the success rate jumps to 60–75%. IHL-42X falls into this second category. Join the ixhl group! Before it’s too late!
0 · Reply